TransMedics Group, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
TMDX$90.95-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | |||||
|---|---|---|---|---|---|
| Other | |||||
| Comprehen- · Total | |||||
| Common Stock · sive Income · Accumulated · Stockholders' | |||||
| Shares | Amount | (Loss) | Deficit | Equity | |
| Balances at December 31, 2022 | 32,141,368 | $666,277 | $(225) | $(478,677) | $187,375 |
| Issuance of common stock upon the exercise of common stock options | 493,935 | 6,155 | — | — | 6,155 |
| Issuance of common stock in connection with employee stock purchase plan | 25,894 | 955 | — | — | 955 |
| Stock-based compensation expense | — | 19,791 | — | — | 19,791 |
| Purchases of capped calls related to convertible senior notes | — | (52,072) | — | — | (52,072) |
| Issuance of restricted common stock | 10,304 | — | — | — | — |
| Restricted common stock forfeitures | (698) | — | — | — | — |
| Foreign currency translation adjustment | — | — | 26 | — | 26 |
| Net loss | — | — | — | (25,028) | (25,028) |
| Balances at December 31, 2023 | 32,670,803 | 641,106 | (199) | (503,705) | 137,202 |
| Issuance of common stock upon the exercise of common stock options | 796,764 | 20,813 | — | — | 20,813 |
| Issuance of common stock in connection with employee stock purchase plan | 31,303 | 2,061 | — | — | 2,061 |
| Issuance of common stock in connection with exercise of warrants | 11,735 | — | — | — | — |
| Issuance of restricted common stock | 4,160 | — | — | — | — |
| Net issuance of common stock upon vesting of restricted stock units | 103,166 | — | — | — | — |
| Conversion of convertible senior notes into common stock | 41 | 4 | — | — | 4 |
| Stock-based compensation expense | — | 33,224 | — | — | 33,224 |
| Foreign currency translation adjustment | — | — | (165) | — | (165) |
| Net income | — | — | — | 35,464 | 35,464 |
| Balances at December 31, 2024 | 33,617,972 | 697,208 | (364) | (468,241) | 228,603 |
| Issuance of common stock upon the exercise of common stock options | 431,771 | 13,746 | — | — | 13,746 |
| Issuance of common stock in connection with employee stock purchase plan | 58,996 | 3,249 | — | — | 3,249 |
| Issuance of restricted common stock | 1,737 | ||||
| Restricted common stock forfeitures | (2,880) | — | — | — | — |
| Net issuance of common stock upon vesting of restricted stock units | 160,206 | (138) | — | — | (138) |
| Stock-based compensation expense | — | 36,861 | — | — | 36,861 |
| Foreign currency translation adjustment | — | — | 488 | — | 488 |
| Net income | — | — | — | 190,291 | 190,291 |
| Balances at December 31, 2025 | 34,267,802 | $750,926 | $124 | $(277,950) | $473,100 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.